Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Amanda Stolarz

TitleAssistant Professor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentPharmaceutical Science, College of Pharmacy
DivisionPharmaceutical Science
Address306A Biomedical Research I
325 S. Elm St.
Mail Slot # 622
Little Rock AR 72205
Phone501-603-1158
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    1R37CA282349     (LANDES, REID D)Aug 10, 2023 - Jul 31, 2028
    NIH/Nat. Cancer Institute
    Ryanodine Receptors as Therapeutic Targets to Prevent Doxorubicin-Induced Lymphatic Dysfunction
    Role: Principal Investigator
    1R37CA282349-01     (LANDES, REID D)Aug 10, 2023 - Jul 31, 2028
    NIH/Nat. Cancer Institute
    Ryanodine Receptors as Therapeutic Targets to Prevent Doxorubicin-Induced Lymphatic Dysfunction
    Role: Principal Investigator
    5R37CA282349     (LANDES, REID D)Aug 10, 2023 - Jul 31, 2028
    NIH/Nat. Cancer Institute
    Ryanodine Receptors as Therapeutic Targets to Prevent Doxorubicin-Induced Lymphatic Dysfunction
    Role: Principal Investigator
    5R37CA282349-02     (LANDES, REID D)Aug 10, 2023 - Jul 31, 2028
    NIH/Nat. Cancer Institute
    Ryanodine Receptors as Therapeutic Targets to Prevent Doxorubicin-Induced Lymphatic Dysfunction
    Role: Principal Investigator
    5R37CA282349-03     (LANDES, REID D)Aug 10, 2023 - Jul 31, 2028
    NIH/Nat. Cancer Institute
    Ryanodine Receptors as Therapeutic Targets to Prevent Doxorubicin-Induced Lymphatic Dysfunction
    Role: Principal Investigator
    5R37CA282349-04     (LANDES, REID D)Aug 10, 2023 - Jul 31, 2028
    NIH/Nat. Cancer Institute
    Ryanodine Receptors as Therapeutic Targets to Prevent Doxorubicin-Induced Lymphatic Dysfunction
    Role: Principal Investigator
    5R37CA282349-05     (LANDES, REID D)Aug 10, 2023 - Jul 31, 2028
    NIH/Nat. Cancer Institute
    Ryanodine Receptors as Therapeutic Targets to Prevent Doxorubicin-Induced Lymphatic Dysfunction
    Role: Principal Investigator
    P20GM109005     (BOERMA, MARJAN)Jun 24, 2015 - May 31, 2025
    NIH
    Center for Studies of Host Response to Cancer Therapy
    Role: Co-Investigator
    R21CA187325     (RUSCH, NANCY J)Mar 9, 2015 - Feb 28, 2018
    NIH
    Doxorubicin suppression of lymphatic function and therapeutic reversal
    Role: Co-Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Liu S, Wu J, Stolarz A, Zhang H, Boerma M, Byrum SD, Rusch NJ, Ding Z. PCSK9 attenuates efferocytosis in endothelial cells and promotes vascular aging. Theranostics. 2023; 13(9):2914-2929. PMID: 37284459.
      View in: PubMed
    2. Stolarz AJ, Chhetri BP, Borrelli MJ, Jenkins SV, Jamshidi-Parsian A, Phillips JH, Fologea D, Gandy J, Griffin RJ. Liposome Formulation for Tumor-Targeted Drug Delivery Using Radiation Therapy. Int J Mol Sci. 2022 Oct 02; 23(19). PMID: 36232973.
      View in: PubMed
    3. Stolarz AJ, Mu S, Zhang H, Fouda AY, Rusch NJ, Ding Z. Opinion: Endothelial Cells - Macrophage-Like Gatekeepers? Front Immunol. 2022; 13:902945. PMID: 35619719.
      View in: PubMed
    4. Pal S, Rahman J, Mu S, Rusch NJ, Stolarz AJ. Drug-Related Lymphedema: Mysteries, Mechanisms, and Potential Therapies. Front Pharmacol. 2022; 13:850586. PMID: 35308247.
      View in: PubMed
    5. Van S, Pal S, Garner BR, Steed K, Sridharan V, Mu S, Rusch NJ, Stolarz AJ. Dantrolene Prevents the Lymphostasis Caused by Doxorubicin in the Rat Mesenteric Circulation. Front Pharmacol. 2021; 12:727526. PMID: 34483938.
      View in: PubMed
    6. Garner BR, Stolarz AJ, Stuckey D, Sarimollaoglu M, Liu Y, Palade PT, Rusch NJ, Mu S. KATP Channel Openers Inhibit Lymphatic Contractions and Lymph Flow as a Possible Mechanism of Peripheral Edema. J Pharmacol Exp Ther. 2021 01; 376(1):40-50. PMID: 33100270.
      View in: PubMed
    7. Stolarz AJ, Sarimollaoglu M, Marecki JC, Fletcher TW, Galanzha EI, Rhee SW, Zharov VP, Klimberg VS, Rusch NJ. Doxorubicin Activates Ryanodine Receptors in Rat Lymphatic Muscle Cells to Attenuate Rhythmic Contractions and Lymph Flow. J Pharmacol Exp Ther. 2019 11; 371(2):278-289. PMID: 31439806.
      View in: PubMed
    8. Stolarz AJ, Lakkad M, Klimberg VS, Painter JT. Calcium Channel Blockers and Risk of Lymphedema among Breast Cancer Patients: Nested Case-Control Study. Cancer Epidemiol Biomarkers Prev. 2019 Nov; 28(11):1809-1815. PMID: 31399477.
      View in: PubMed
    9. Sarimollaoglu M, Stolarz AJ, Nedosekin DA, Garner BR, Fletcher TW, Galanzha EI, Rusch NJ, Zharov VP. High-speed microscopy for in vivo monitoring of lymph dynamics. J Biophotonics. 2018 08; 11(8):e201700126. PMID: 29232054.
      View in: PubMed
    10. Stolarz AJ, Farris RA, Wiley CA, O'Brien CE, Price ET. Fenofibrate Attenuates Neutrophilic Inflammation in Airway Epithelia: Potential Drug Repurposing for Cystic Fibrosis. Clin Transl Sci. 2015 Dec; 8(6):696-701. PMID: 26258991.
      View in: PubMed
    11. Stolarz AJ, Rusch NJ. Gender Differences in Cardiovascular Drugs. Cardiovasc Drugs Ther. 2015 Aug; 29(4):403-10. PMID: 26227895.
      View in: PubMed
    Stolarz's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (67) concept(s)
    _
    Co-Authors Expand Description
    See all (16) people
    _
    Similar People Expand Description
    See all (31) people
    _
    Same Department Expand Description
    Search Department